- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03404115
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
July 10, 2019 updated by: Aldeyra Therapeutics, Inc.
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects with Dry Eye Disease
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
300
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
Waterbury, Connecticut, United States, 06708
- The Eye Care Group
-
-
Indiana
-
Indianapolis, Indiana, United States, 46290
- Midwest Cornea Associates
-
-
Maine
-
Lewiston, Maine, United States, 04240
- Central Maine Eye Care
-
-
Massachusetts
-
Andover, Massachusetts, United States, 01810
- Andover Eye Associates
-
Raynham, Massachusetts, United States, 02767
- Andover Eye Associates
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Total Eye Care
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be at least 18 years of age of either gender and any race;
- Have a reported history of dry eye for at least 6 months prior to Visit 1;
- Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1;
Exclusion Criteria:
- Have any clinically significant slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
- Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
- Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
- Have used any eye drops within 2 hours of Visit 1;
- Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
- Have used cyclosporine 0.05% or lifitigrast 5.0% ophthalmic solution within 90 days of Visit 1;
- Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1;
- Be using or anticipate using temporary punctal plugs during the study that have not been stable within 30 days of Visit 1;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Reproxalap Ophthalmic Solution (0.25%)
|
Reproxalap Ophthalmic Solution (0.25%) administered for approximately twelve weeks.
|
Placebo Comparator: Vehicle Ophthalmic Solution
|
Vehicle Ophthalmic Solution administered for approximately twelve weeks.
|
Experimental: Reproxalap Ophthalmic Solution (0.1%)
|
Reproxalap Ophthalmic Solution (0.1%) administered for approximately twelve weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess safety and tolerability of reproxalap formulations using adverse event query.
Time Frame: Safety Assessment Period (Day -14 to Day 85)
|
Evaluate the safety and tolerability of reproxalap formulations in subjects with dry eye syndrome.
|
Safety Assessment Period (Day -14 to Day 85)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of reproxalap on Lissamine green staining using the Ora Calibra® scale.
Time Frame: Efficacy assessment period (Day 1 through Day 85)
|
Evaluate lissamine green staining of reproxalap in subjects with dry eye syndrome.
|
Efficacy assessment period (Day 1 through Day 85)
|
Efficacy of reproxalap on fluorescein staining using the Ora Calibra® scale.
Time Frame: Efficacy assessment period (Day 1 through Day 85)
|
Evaluate fluorescein staining of reproxalap in subjects with dry eye syndrome.
|
Efficacy assessment period (Day 1 through Day 85)
|
Efficacy of reproxalap on tear film break-up time (TFBUT©).
Time Frame: Efficacy assessment period (Day 1 through Day 85)
|
Evaluate tear film break-up time of reproxalap in subjects with dry eye syndrome.
|
Efficacy assessment period (Day 1 through Day 85)
|
Efficacy of reproxalap on ocular discomfort using the Ora Calibra® Ocular Discomfort scale.
Time Frame: Efficacy assessment period (Day 1 through Day 85)
|
Evaluate the symptoms of reproxalap on ocular discomfort in subjects with dry eye syndrome.
|
Efficacy assessment period (Day 1 through Day 85)
|
Efficacy of reproxalap on dry eye syndrome using the Ocular Surface and Disease Index (OSDI) © questionnaire.
Time Frame: Efficacy assessment period (Day 1 through Day 85)
|
Evaluate the symptoms of reproxalp in subjects with dry eye syndrome.
|
Efficacy assessment period (Day 1 through Day 85)
|
Efficacy of reproxalap on dry eye syndrome symptoms using the Symptom Assessment in Dry Eye (SANDE) scale.
Time Frame: Efficacy assessment period (Day 1 through Day 85)
|
Evaluate the dry eye symptoms of reproxalap in subjects with dry eye syndrome.
|
Efficacy assessment period (Day 1 through Day 85)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 2, 2018
Primary Completion (Actual)
July 11, 2018
Study Completion (Actual)
July 11, 2018
Study Registration Dates
First Submitted
January 12, 2018
First Submitted That Met QC Criteria
January 12, 2018
First Posted (Actual)
January 19, 2018
Study Record Updates
Last Update Posted (Actual)
July 16, 2019
Last Update Submitted That Met QC Criteria
July 10, 2019
Last Verified
January 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADX-102-DED-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Syndrome
-
Olympic Ophthalmics, Inc.RecruitingMicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye SyndromeUnited States
-
Fidia Farmaceutici s.p.a.RecruitingDry Eye Syndrome (DES)Italy
-
Instituto Universitario de Oftalmobiología Aplicada...Completed
-
Santen SASCompletedModerate to Severe Dry Eye SyndromeFrance
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Applied Science & Performance InstituteTrue Eye Experts - New Tampa; True Eye Experts - Lutz; True Eye Experts - South...CompletedDry Eye | Dry Eye SyndromesUnited States
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
ReGenTree, LLCCompletedDry Eye | Dry Eye SyndromesUnited States
-
OphRx Ltd.CompletedDry Eye SyndromesIsrael
-
University of New MexicoWithdrawn
Clinical Trials on Reproxalap Ophthalmic Solution (0.25%)
-
Aldeyra Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States
-
Aldeyra Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States
-
Aldeyra Therapeutics, Inc.Completed
-
Aldeyra Therapeutics, Inc.Completed
-
Aldeyra Therapeutics, Inc.Completed
-
Aldeyra Therapeutics, Inc.Completed
-
Aldeyra Therapeutics, Inc.CompletedAllergic ConjunctivitisCanada
-
Aldeyra Therapeutics, Inc.CompletedDry Eye SyndromesCanada
-
Aldeyra Therapeutics, Inc.CompletedAllergic ConjunctivitisCanada
-
Aldeyra Therapeutics, Inc.CompletedDry Eye | Dry Eye SyndromesUnited States